Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Affinia Therapeutics raises $110 million for gene therapy treatments
By Jonathan Saltzman Boston Globe May 4, 2021Reprints
Adobe
Affinia Therapeutics, a Waltham-based biotech working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear, said Monday it has raised $110 million in a new venture capital round.
The company, which was founded in 2019 based on work pioneered by Luk Vandenberghe, an associate professor at Mass. Eye and Ear and Harvard Medical School, plans to use the money to advance its gene therapy technology and move experimental drug programs into clinical trials. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affinia Therapeutics Closes $110 Million Series B Financing
Affinia TherapeuticsMay 3, 2021 GMT Financing co-led by EcoR1 Capital and Farallon Capital Management
Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Cap
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Immune system could turn on the vaccine Need for repeat shots seen likely as variants evolve UK government aware of vector immunity issue
ZURICH, Feb 26 (Reuters) - Vaccines from AstraZeneca , Russia’s Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual inoculations become necessary to fight new variants.
So-called viral vector shots - also used by several Chinese COVID-19 vaccine developers - use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections.
However, there is a risk that the body also develops immunity to the vector itself, recognising it as an intruder and trying to destroy it.